Anaphylaxis and anaphylactic shock
The anaphylactic shock is an acute, multisystemic and potentially fatal circulatory insufficiency, secondary to an allergic reaction. The prevalence of anaphylaxis is underestimated in the general population. Many studies have reported a prevalence of 0.05-2%. Multiple etiologies are incriminated in the pathogenesis of anaphylaxis, and these etiologies vary depending on age and geographic zones. The clinical manifestations of anaphylaxis are multiple, owing to the multisystemic character of this pathology. The gold standard in management of anaphylaxis is thought to be the rapid and early administration of epinephrine by intra-muscular route. The prevention of anaphylaxis remains the treatment of choice. Educating the patient is an important aspect of anaphylaxis follow-up along with the prescription of epinephrine autoinjectors.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 10(2014), 438 vom: 13. Aug., Seite 1511-5 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Anaphylaxie et etat de choc anaphylactique |
|---|
| Beteiligte Personen: |
Abi Khalil, Muriel [VerfasserIn] |
|---|
| Themen: |
Bronchodilator Agents |
|---|
| Anmerkungen: |
Date Completed 20.10.2014 Date Revised 09.09.2014 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM241692059 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM241692059 | ||
| 003 | DE-627 | ||
| 005 | 20231224124812.0 | ||
| 007 | tu | ||
| 008 | 231224s2014 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n0805.xml |
| 035 | |a (DE-627)NLM241692059 | ||
| 035 | |a (NLM)25199227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Abi Khalil, Muriel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anaphylaxis and anaphylactic shock |
| 246 | 3 | 3 | |a Anaphylaxie et etat de choc anaphylactique |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 20.10.2014 | ||
| 500 | |a Date Revised 09.09.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The anaphylactic shock is an acute, multisystemic and potentially fatal circulatory insufficiency, secondary to an allergic reaction. The prevalence of anaphylaxis is underestimated in the general population. Many studies have reported a prevalence of 0.05-2%. Multiple etiologies are incriminated in the pathogenesis of anaphylaxis, and these etiologies vary depending on age and geographic zones. The clinical manifestations of anaphylaxis are multiple, owing to the multisystemic character of this pathology. The gold standard in management of anaphylaxis is thought to be the rapid and early administration of epinephrine by intra-muscular route. The prevention of anaphylaxis remains the treatment of choice. Educating the patient is an important aspect of anaphylaxis follow-up along with the prescription of epinephrine autoinjectors | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Epinephrine |2 NLM | |
| 650 | 7 | |a YKH834O4BH |2 NLM | |
| 700 | 1 | |a Damak, Hassen |e verfasserin |4 aut | |
| 700 | 1 | |a Décosterd, Dumeng |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 10(2014), 438 vom: 13. Aug., Seite 1511-5 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2014 |g number:438 |g day:13 |g month:08 |g pages:1511-5 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2014 |e 438 |b 13 |c 08 |h 1511-5 | ||